CBAY
Cymabay Therapeutics
CBAY
CBAY
Delisted
CBAY was delisted on the 21st of March, 2024.
100 hedge funds and large institutions have $218M invested in Cymabay Therapeutics in 2022 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 30 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
40% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 30
Holders
100
Holding in Top 10
6
Calls
$865K
Puts
$520K
Top Buyers
| 1 | +$2.8M | |
| 2 | +$2.09M | |
| 3 | +$1.19M | |
| 4 |
Two Sigma Advisers
New York
|
+$813K |
| 5 |
Walleye Capital
New York
|
+$770K |
Top Sellers
| 1 | -$5.19M | |
| 2 | -$1.03M | |
| 3 | -$923K | |
| 4 |
Morgan Stanley
New York
|
-$861K |
| 5 |
PCM
Pinz Capital Management
New York
|
-$683K |